drugset / Trial / NCT03187795
Mirabegron and Oxybutynin Safety and Efficacy Trial in Spinal Cord Injury
Phase 2
Unknown
62 enrolled
Kessler Foundation
National Institute on Disability, Independent Living, and Rehabilitation Research · collab
RandomizedCrossoverQuadruple-blindTreatment
Summary
The purpose of this research study is to determine the effectiveness and safety of mirabegron compared to oxybutynin chloride immediate release (oxybutynin IR) for a condition called neurogenic detrusor overactivity in individuals with chronic spinal cord injury (SCI).
Timeline
- Start
- 2019-04-03
- Primary completion
- 2021-09-30
- Completion
- 2022-03-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mirabegron | Other / unclassified | 50 mg | — |
| Subject | Oxybutynin Chloride IR | Unknown | 5 mg | — |